Recent Posts
- Press Release Sun Pharma reports Q2 & half year results for FY27
- SPIL Q2FY27 Financial Results
- At ESMO 2026, Sun Pharma to Present Long-Term Follow-up Data on UNLOXCYT® (cosibelimab-ipdl) from One of the Largest Prospective Studies in Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)
- Sun Pharma Announces UNLOXCYT® (cosibelimab-ipdl) Has Received a Category 2A Preferred Designation in the Updated NCCN Guidelines for Locally Advanced Cutaneous Squamous Cell Carcinoma
- Sun Pharma Establishes Endowed Professorship at Mount Sinai to Advance Dermatologic Care
Recent Comments